Copy to clipboard 
Alphatec Spine reported 3Q19 revenue of USD $29.2MM, +26.9% vs. 3Q18.
- Alphatec updated 2019 full year revenue guidance to the range of $109MM (+19%) to $112MM (+22%)
- Year to date the company has launched 11 new products (four in 3Q19), expanded revenue contribution from new products to 33%, drove revenue growth from strategic distributors to 41% and grew revenue per surgery by 15% (17% in 3Q19) as surgeon adoption of products increases
- Products launched within the quarter include IdentiTi ALIF, InVictus MIS Single-Step, InVictus Open and IdentiTi TLIF-PO
- Leadership is excited about the clinical distinction that will be created by the November 2019 full launch of SafeOp, the neuromonitoring component of the Alpha InformatiX platform, and expects it to be a key factor in selling entire surgical approaches with an associated increase of products sold per surgery
- ORTHOWORLD projects Alphatec full year 2019 revenue of $110.6MM, +20.7% vs. 2018
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM).
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Spine | $26.7 | $21.0 | $5.7 | 27% |
| Orthobiologics | $2.5 | $2.0 | $0.5 | 26.2% |
| Total | $29.2 | $23.0 | $6.2 | 26.9% |
| 9Mo 19 | 9Mo 18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Spine | $74.0 | $60.3 | $13.7 | 22.6% |
| Orthobiologics | $7.1 | $6.0 | $1.1 | 18.7% |
| Total | $81.1 | $66.3 | $14.8 | 22.3% |
ORTHOWORLD estimates orthopedic sales by geographic region as follows ($MM).
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $28.1 | $21.0 | $7.1 | 33.6% |
| Ex-US | $1.2 | $2.0 | ($0.9) | (42.7%) |
| Total | $29.2 | $23.0 | $6.2 | 26.9% |
Net earnings are as follows ($MM).
| Amt | % of Sales | |
|---|---|---|
| Sales | $29.2 | |
| Cost of Sales | ($9.3) | 31.7% |
| Selling and Admin | ($26.8) | 91.8% |
| R & D | ($4.0) | 13.6% |
| Other | ($0.8) | 2.7% |
| Net Earnings | ($11.6) | (39.7%) |
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
Alphatec Spine reported 3Q19 revenue of USD $29.2MM, +26.9% vs. 3Q18.
Alphatec updated 2019 full year revenue guidance to the range of $109MM (+19%) to $112MM (+22%)
Year to date the company has launched 11 new products (four in 3Q19), expanded revenue contribution from new products to 33%, drove revenue growth from strategic...
Alphatec Spine reported 3Q19 revenue of USD $29.2MM, +26.9% vs. 3Q18.
- Alphatec updated 2019 full year revenue guidance to the range of $109MM (+19%) to $112MM (+22%)
- Year to date the company has launched 11 new products (four in 3Q19), expanded revenue contribution from new products to 33%, drove revenue growth from strategic distributors to 41% and grew revenue per surgery by 15% (17% in 3Q19) as surgeon adoption of products increases
- Products launched within the quarter include IdentiTi ALIF, InVictus MIS Single-Step, InVictus Open and IdentiTi TLIF-PO
- Leadership is excited about the clinical distinction that will be created by the November 2019 full launch of SafeOp, the neuromonitoring component of the Alpha InformatiX platform, and expects it to be a key factor in selling entire surgical approaches with an associated increase of products sold per surgery
- ORTHOWORLD projects Alphatec full year 2019 revenue of $110.6MM, +20.7% vs. 2018
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM).
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Spine | $26.7 | $21.0 | $5.7 | 27% |
| Orthobiologics | $2.5 | $2.0 | $0.5 | 26.2% |
| Total | $29.2 | $23.0 | $6.2 | 26.9% |
| 9Mo 19 | 9Mo 18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Spine | $74.0 | $60.3 | $13.7 | 22.6% |
| Orthobiologics | $7.1 | $6.0 | $1.1 | 18.7% |
| Total | $81.1 | $66.3 | $14.8 | 22.3% |
ORTHOWORLD estimates orthopedic sales by geographic region as follows ($MM).
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $28.1 | $21.0 | $7.1 | 33.6% |
| Ex-US | $1.2 | $2.0 | ($0.9) | (42.7%) |
| Total | $29.2 | $23.0 | $6.2 | 26.9% |
Net earnings are as follows ($MM).
| Amt | % of Sales | |
|---|---|---|
| Sales | $29.2 | |
| Cost of Sales | ($9.3) | 31.7% |
| Selling and Admin | ($26.8) | 91.8% |
| R & D | ($4.0) | 13.6% |
| Other | ($0.8) | 2.7% |
| Net Earnings | ($11.6) | (39.7%) |
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
